| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | EDG2; LPA1; VZG1; GPR26; edg-2; vzg-1; Gpcr26; Mrec1.3; rec.1.3 |
| WB Predicted band size | 41 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human LPAR1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于LPAR1抗体的3-4条参考文献示例(内容为虚构，仅供格式参考)：
---
1. **标题**：*LPAR1-Specific Antibody Inhibits Tumor Growth by Blocking Lysophosphatidic Acid Signaling in Breast Cancer*
**作者**：Chen Y, et al.
**摘要**：本研究开发了一种高特异性LPAR1单克隆抗体，通过阻断LPA-LPAR1信号通路，显著抑制乳腺癌细胞的迁移和侵袭。实验表明，该抗体在异种移植模型中可减少肿瘤生长和转移，提示其作为潜在治疗工具的潜力。
2. **标题**：*Validation of a Novel LPAR1 Antibody for Immunohistochemical Analysis in Pulmonary Fibrosis*
**作者**：Smith RJ, et al.
**摘要**：文章报道了一种新型兔源多克隆LPAR1抗体的开发与验证。该抗体在肺纤维化患者组织中显示出高灵敏度和特异性，成功用于检测肺泡上皮细胞中LPAR1的异常表达，为纤维化机制研究提供可靠工具。
3. **标题**：*LPAR1 Neutralizing Antibody Attenuates Neuropathic Pain via Modulation of Glial Cell Activation*
**作者**：Tanaka K, et al.
**摘要**：研究利用LPAR1中和抗体阻断脊髓中的LPA信号，发现其可显著减少神经病理性疼痛模型中的胶质细胞活化和炎症因子释放，表明靶向LPAR1的抗体策略在疼痛治疗中的应用前景。
4. **标题**：*Comparative Study of Commercial LPAR1 Antibodies for Flow Cytometry Applications*
**作者**：Müller S, et al.
**摘要**：本文对比了5种市售LPAR1抗体在流式细胞术中的性能，发现克隆号3A10的抗体在检测T细胞表面LPAR1时具有最优信噪比，为免疫学研究中的抗体选择提供了实验依据。
---
以上文献摘要涵盖了LPAR1抗体在癌症治疗、疾病机制研究、工具抗体验证及疼痛治疗等领域的应用。如需真实文献，建议通过PubMed或Web of Science以“LPAR1 antibody”为关键词检索。
The lysophosphatidic acid receptor 1 (LPAR1), a G protein-coupled receptor (GPCR) belonging to the endothelial differentiation gene (EDG) family, mediates cellular responses to lysophosphatidic acid (LPA), a bioactive phospholipid involved in diverse physiological and pathological processes. LPAR1 plays critical roles in cell proliferation, migration, and survival, with implications in cancer progression, fibrosis, inflammation, and neurological disorders. Antibodies targeting LPAR1 are valuable tools for studying its expression, activation mechanisms, and signaling pathways in both normal and diseased tissues.
LPAR1 antibodies are widely used in techniques like immunohistochemistry (IHC), Western blotting, and flow cytometry to map receptor localization and quantify expression levels in preclinical models or clinical samples. Dysregulation of LPAR1 has been observed in cancers (e.g., ovarian, breast), fibrotic diseases (e.g., pulmonary, renal fibrosis), and neurodegenerative conditions, making it a potential therapeutic target. Researchers also employ LPAR1-neutralizing antibodies to inhibit LPA-induced signaling cascades, exploring their therapeutic potential in blocking tumor metastasis or fibrotic remodeling. Recent studies focus on developing monoclonal antibodies with high specificity to advance diagnostic assays or targeted therapies. Additionally, LPAR1 antibodies contribute to elucidating receptor-ligand interactions and downstream effectors, aiding drug discovery efforts for small-molecule antagonists. Their utility extends to biomarker research, as LPAR1 overexpression often correlates with disease severity and prognosis.
×
